Related News
Oct 20, 2026
OpenAI buys Orchestra Bio to add workflow agents to its drug-development stack
OpenAI has acquired Orchestra Bio and plans to integrate its drug-program coordination software with Rosalind, GPT-Rosalind and Rosalind Workbench. The deal expands OpenAI from research models into the operational layer around medicine development, but the price, product continuity and any effect on treatment timelines remain undisclosed or unproven.
Oct 18, 2026
Eight states sued OpenAI over ChatGPT safety — here is what happens now
Eight states filed separate consumer-protection cases over ChatGPT's design, safety claims and treatment of minors. The filings are allegations, no court has ruled, and OpenAI says it has protections for younger users.
Oct 18, 2026
FTC demands reportedly target OpenAI and Anthropic. That is not a verdict
Axios reports that the FTC sent civil investigative demands to OpenAI and Anthropic over possible consumer-protection concerns. The requests can compel evidence, but they do not establish a violation or penalty.